Scotland expands NHS weight-loss jab Wegovy for at‑risk patients
Scotland's NHS will offer Wegovy (semaglutide) to overweight patients with cardiovascular risk after approval by the Scottish Medicines Consortium; eligible individuals must have a BMI of 27+ with health risk factors, with about 145,000 Scots potentially eligible. The drug is self-administered at home, may reduce major cardiovascular events beyond weight loss, and can cause side effects like bloating or nausea; rollout follows England's approval and aims to widen access to effective obesity treatments.